Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets

Table 1

Summary of clinical trials in anti-CS1/SLAMF7 antibody in relapsed/refractory MM.

References		Phase	Regimen	ORR (%)	PFS (mo)	OS
Richardson et al. [17]		2	Elo + Rd	84.00%	NA	NA
Lonial et al. [18]	ELOAUENT2	3	Rd ± Elo	79% vs 66%	19.4 mo vs 14.9 mo	NA
Dimopoulos et al. [12]		2	Pd ± Elo	53% vs 26%	10.3 mo vs 4.7 mo	NA
Jakubowiak et al. [20]	Elo-Bd	2	Bd ± Elo	66% vs 63%	9.7 mo vs 6.9 mo	1 yr 85% vs 74%
Zonder et al. [16]	Phase1 Elo	1	Elo Dose Escalation	MTD not identified	NA	NA
Jakubowiak, et al. [21]	Elo-Bd	1	Elo + Bd	48.00%	9.5 mo	NA
Lonial, et al. [19]	Elo-Rd	1	Elo + Rd	82.00%	NA	NA

MM, multiple myeloma; Elo, elotuzumab; Rd, lenalidomide plus dexamethasone; Pd, pomalidomide plus dexamethasone; Bd, bortezomib plus dexamethasone, NA, not available; MTD, maximum tolerated dose.